The National Institute for Care and Excellence (NICE) has recommended Roche’s Columvi (glofitamab) for NHS use as a treatment option for a type of blood cancer known as diffuse large B-cell lymphoma (DLBCL).
Over 700 people in the UK are set to benefit from the new treatment following approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and NICE.
Columvi will be available as a treatment option for adult patients with relapsed or refractory DLBCL after two or more previous systemic treatments…
